SROA SoundBoard - Sam Mazin

05/04/2023

Questions Answered During Podcast: 

1. When you presented at SROA's annual meeting in 2019, RefleXion was still in startup mode. Can you briefly share what's happened since then? 
2. When you presented in 2019, there was some skepticism about the technology, maybe because it's new and different. How would you respond now that you have the approval? 
3. The FDA clearance that you received earlier this month for the BGRT, now called SCINTIX, is really significant. Can you explain why? 
4. How would you position RefleXion to administrators looking at tighter budgets and shorter courses of treatment? 
5. Going back to SCINTIX, why did you change the name from BGRT to SCINTIX? 
6. How has your vision for the technology and how it can be used changed since you started and especially maybe over the last few years? 
7. How does SCINTIX fit within adaptive radiotherapy planning and precision medicine? 
8. Do you see RefleXion becoming a big player in the radiation oncology treatment landscape or market alongside the other big names? 
9. What's next for RefleXion, say, this year and in the next five years? 
10. What would you like administrators to know?